Dr. Leanne Bedard received her PhD in Pharmacology and Toxicology from Queen’s University (Kingston, ON, Canada) in 2004. Leanne began her career in pharmaceutical research in 2006 at Merck Frosst in Montréal where she was the recipient of a Special Achievement Award for her contribution to the discovery of PIFELTRO™, a non-nucleoside reverse transcriptase inhibitor, now marketed for the treatment of HIV. She then joined AstraZeneca R&D Montréal as a DMPK Drug Design Leader. For over a decade, Leanne has worked as an independent consultant in nonclinical drug metabolism, pharmacokinetics and toxicology. She has worked with over 100 biotech and small pharma companies located in Canada and in the US. She has contributed to the discovery, nonclinical development, and successful regulatory filing of several small molecule investigational new drugs and marketing authorizations in jurisdictions worldwide (USA, Europe, UK, Canada, Australia and Japan). Leanne has also served as a Nonclinical Pharm/Tox Reviewer for over a dozen New Drug Submissions to the Therapeutic Products Directorate at Health Canada.
Leanne is a Diplomate of ABT and hold a certification in Regulatory Affairs. She is the sole author of the book chapter on Toxicokinetics for the revised 7th Edition of the quintessential toxicology textbook, Hayes’ Principles and Methods of Toxicology. Leanne is also a speaker in ACT’s Toxicology for Pharmaceutical and Regulatory Scientists and Advanced Comprehensive Toxicology courses. She has served on ACT’s Program Committee. Leanne has served the Society of Toxicology of Canada as Councilor on the Board of Directors and as Program Committee Chair.